Austin Aerts Biography and Net Worth

Strategic Advisor of Sera Prognostics

Austin Aerts serves as a strategic advisor to Sera Prognostics, providing guidance on key initiatives and supporting operational continuity. Since joining the Company in 2017, he held multiple finance leadership roles, including Chief Financial Officer, and played a pivotal role in Sera’s successful initial public offering and transition to the public markets. Prior to Sera, he worked at Myriad Genetics and Ernst & Young LLP. Austin holds a Master of Accounting from the University of Utah and is a Certified Public Accountant licensed in the State of Utah.

What is Austin Aerts' net worth?: The estimated net worth of Austin Aerts is at least $627.68 thousand as of June 9th, 2026. Mr. Aerts owns 303,227 shares of Sera Prognostics stock worth more than $627,680 as of September 18th. This net worth estimate does not reflect any other investments that Mr. Aerts may own. Learn More about Austin Aerts' net worth.
How do I contact Austin Aerts?: The corporate mailing address for Mr. Aerts and other Sera Prognostics executives is 2749 E. Parleys Way, Suite 200, Salt Lake City, UT, 84109. Sera Prognostics can also be reached via phone at 801-990-0520 and via email at [email protected]. Learn More on Austin Aerts' contact information.
Has Austin Aerts been buying or selling shares of Sera Prognostics?: Austin Aerts has not been actively trading shares of Sera Prognostics during the last quarter. Most recently, Austin Aerts sold 5,440 shares of the business's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a transaction totalling $11,315.20. Following the completion of the sale, the chief financial officer now directly owns 303,227 shares of the company's stock, valued at $630,712.16. Learn More on Austin Aerts' trading history.
Who are Sera Prognostics' active insiders?: Sera Prognostics' insider roster includes Austin Aerts (Strategic Advisor), Benjamin Jackson (General Counsel), Paul Kearney (Data Science Advisor), and Sandra Lawrence (Director). Learn More on Sera Prognostics' active insiders.
Are insiders buying or selling shares of Sera Prognostics?: In the last twelve months, insiders at the sold shares 39 times. They sold a total of 167,112 shares worth more than $394,436.33. The most recent insider tranaction occured on September, 10th when insider Dyaarl Lee Jr. Anderson sold 1,800 shares worth more than $3,600.00. Insiders at Sera Prognostics own 11.3% of the company. Learn More about insider trades at Sera Prognostics.
Information on this page was last updated on 9/10/2026.

Austin Aerts Insider Trading History at Sera Prognostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2026	Sell	5,440	$2.08	$11,315.20	303,227
3/11/2026	Sell	1,019	$2.04	$2,078.76	264,452
3/10/2026	Sell	6,069	$1.90	$11,531.10	265,471
3/9/2026	Sell	674	$1.96	$1,321.04	271,540
12/10/2025	Sell	873	$3.31	$2,889.63	272,214
12/9/2025	Sell	5,232	$3.04	$15,905.28	273,087
9/11/2025	Sell	915	$3.13	$2,863.95	284,670
9/9/2025	Sell	5,263	$3.15	$16,578.45	285,585
6/10/2025	Sell	945	$1.48	$1,398.60	296,648
6/9/2025	Sell	5,735	$1.43	$8,201.05	297,593
5/8/2025	Sell	6,374	$2.44	$15,552.56	303,328
3/6/2025	Sell	540	$4.16	$2,246.40	314,520
1/10/2025	Sell	2,431	$8.06	$19,593.86	283,325
11/11/2024	Sell	7,179	$7.32	$52,550.28	291,486
9/10/2024	Sell	5,056	$7.57	$38,273.92	298,665
8/7/2024	Sell	6,760	$7.42	$50,159.20	303,721
6/10/2024	Sell	5,415	$8.11	$43,915.65	310,481
5/8/2024	Sell	6,592	$9.59	$63,217.28	315,896
3/26/2024	Sell	8,092	$9.37	$75,822.04	322,488
2/6/2024	Sell	9,786	$8.03	$78,581.58	331,024

Austin Aerts Buying and Selling Activity at Sera Prognostics

Sera Prognostics Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $2.07

$2.04

$2.08

50 Day Range

MA: $2.05

$1.92

$2.27

2 Week Range

Now: $2.07

$1.56

$3.95

Volume

7,205 shs

Average Volume

23,442 shs

Market Capitalization

$81.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98